Comprehensive Demographics and Clinical Profile of NSCLC Patients

Launched by D'OR INSTITUTE FOR RESEARCH AND EDUCATION · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how doctors choose the first treatment options for patients with advanced non-small cell lung cancer (NSCLC) who do not have specific genetic changes known as driver mutations. The study will review patient information from 2019 to 2022 across seven medical centers in Brazil to better understand treatment patterns and how different factors influence these choices. This is important because recent advancements have provided more options for treating this type of lung cancer.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of advanced non-small cell lung cancer. They also need to have their health information documented in their medical records. However, patients with earlier-stage lung cancer that can still be treated locally, or those with certain other types of tumors, will not be included. Since the study is not yet recruiting, there is no immediate action needed. Participants in this trial can expect their data to contribute to a better understanding of treatment decisions in lung cancer care, which may help improve future patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years old;
• • Histological diagnosis of advanced non-small cell cancer;
• • Clinical and demographic data available in medical records;
• Exclusion Criteria:
• • Patients with localized disease that can be treated locally;
• • Non-epithelial histology;
• • small cell carcinoma
• • neuroendocrine tumor